Page 59 - AN-4-2

Advanced Neurology George Cotzias and L-DOPA therapy

68. Diamond GS, Markham HC, Hoehn MM, McDowell HM, com/2016/10/16/1990-awakenings [Last accessed on
Muenter DM. Multi-center study of Parkinson mortality 2024 Dec 12].
with early versus later DOPA treatment. Ann Neurol. 76. Chagraoui A, Boulain M, Juvin L, et al. L-DOPA in
1986;22(1):8-12. Parkinson’s disease: Looking at the “false” neurotransmitters
doi: 10.1002/ana.410220105 and their meaning. Int J Mol Sci. 2020;21:1-23.
69. Parenti M, Flauto C, Parati E, Vescovi A, Groppetti A. doi: 10.3390/ijms21010294
Manganese neurotoxicity: Effects of L-DOPA and pargyline 77. Kipfer S, Stephan AM, Schupbach MMW, Ballinari P,
treatments. Brain Res. 1986;367:8-13. Kaelin-Lang A. Resting tremor in Parkinson disease. Arch
doi: 10.1016/0006-8993(86)91571-4 Neurol. 2011;68(8):1037-1039.
70. Li L, Zhou FM. Parallel dopamine D1 receptor activity doi: 10.1001/archneurol.2011.147
dependence of L-DOPA-induced normal movement and 78. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-
dyskinesia in mice. Neuroscience. 2013;236:66-76. L-DOPA (IPX066) compared with immediaterelease
doi: 10.1016/j.neuroscience.2012.12.065 carbidopa-L-DOPA in patients with Parkinson’s disease and
motor fluctuations: A phase 3 randomised, double-blind
71. Cotzias G, Miller S, Tang L, Papavasiliou P. L-DOPA, trial. Lancet Neurol. 2013:12;346-356.
fertility, and longevity. Science. 1977;196:549-551.
doi: 10.1016/S1474-4422(13)70025-5
doi: 10.1126/science.850799
79. Zach H, Dirkx MF, Roth D, Pasman JW, Bloem BR,
72. Mena I, Cotzias GC. Protein intake and treatment Helmich RC. Dopamine-responsive and dopamine-
of Parkinson’s Disease with L-DOPA. N Engl J Med. resistant resting tremor in Parkinson disease. Neurology.
1975;292:181-184. 2020:95(11);1461-1470.
doi: 10.1056/NEJM197501232920404 doi: 10.1212/WNL.0000000000010316
73. Sacks O. Awakenings. 2 ed. United States: Random House, 80. Lees A, Turner K. How to do it apomorphine for Parkinson’s
nd
Inc.; 1976. p. 42-258. disease. Pract Neurol. 2002;2:280-286.
74. Sacks O. Awakenings. 2 ed. United States: Random House, 81. Espay JA, Pagan LF, Walter LB, et al. Optimizing extended-
nd
Inc.; 1976. p. 259-284. release carbidopa/L-DOPA in Parkinson disease. Neurol
Clin Pract. 2017;7:86-93.
75. Fictional Movie. Awakenings. Production: LASKER/
PARKES, Direction: Penny Marshall, Script: Oliver Sacks and 82. Mylonas AG. Cotzias: The great benefactor (γ. κοτζιασ: ο
Steven Zaillian. Available from: https://www.oscarchamps. μεγαλοσ ευεργετησ). Giatrevo. 2015;34:34-35.

Volume 4 Issue 2 (2025) 53 doi: 10.36922/an.5177